on Wednesday announced that the U.S. FDA cleared its Tempus ECG-AF device designed to leverage artificial intelligence to help detect patients at risk of developing a heart condition known as ...

Another notable regulatory achievement was the CMS reimbursement approval for cardiac dysfunction assessments using the Tempus ECG-AF algorithm, with a reimbursement rate of $138 per algorithm.